Better Buy: Gilead Sciences vs. Biogen

Biotech stocks have had a turbulent first quarter this year, to say the least. With the COVID-19 pandemic continuing to escalate, many companies have jumped on the chance to develop a potential treatment. At the same time, it's easy to overlook biotech companies that are staying out of the COVID-19 market for one reason or another.

Both Gilead Sciences (NASDAQ: GILD) and Biogen (NASDAQ: BIIB) are biotech giants with plenty of good things going for them. However, they are different in many ways as well, including the fact that one of them has a promising COVID-19 treatment in the works and the other could have a blockbuster Alzheimer's treatment on the horizon.

Let's take a look at which of these companies is a better investment at this time -- if you had to choose between the two.

Continue reading

Source Fool.com